CSIMarket
 


Prothena Corporation Public Limited Company  (PRTA)
Other Ticker:  
 
 

PRTA's Net Cash Flow Growth by Quarter and Year

Prothena Public Limited's Net Cash Flow results by quarter and year




PRTA Net Cash Flow (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December -52.07 132.17 -21.00 -80.34
III Quarter September -39.51 70.30 198.92 0.00
II Quarter June 24.22 -34.20 56.84 23.04
I Quarter March -24.22 -36.10 47.61 -23.04
FY   -91.58 132.17 282.37 -80.34



PRTA Net Cash Flow fourth quarter 2023 Y/Y Growth Comment
Prothena Corporation Public Limited Company in the fourth quarter 2023 recorded net cash outflow of $ -52.07 millions.

Among companies who have reported fourth quarter 2023 results in the Major Pharmaceutical Preparations industry only one Company has achieved higher year on year Net Cash Flow results in the fourth quarter 2023. While Prothena Corporation Public Limited Company' s Net Cash Flow no change of % ranks overall at the positon no. 119 in the fourth quarter 2023.




PRTA Net Cash Flow ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - -64.66 % - -
II Quarter June - - 146.7 % -
I Quarter March - - - -
FY   - -53.19 % - -

Financial Statements
Prothena Public Limited's fourth quarter 2023 Net Cash Flow $ -52.07 millions PRTA's Income Statement
Prothena Public Limited's fourth quarter 2022 Net Cash Flow $ 132.17 millions Quarterly PRTA's Income Statement
New: More PRTA's historic Net Cash Flow Growth >>


PRTA Net Cash Flow (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - 88.01 % - -
III Quarter September - - 249.96 % -
II Quarter June - - 19.39 % -
I Quarter March - - - -
FY (Year on Year)   - -53.19 % - -




Net Cash Flow fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #2
Healthcare Sector #8
Overall #119

Net Cash Flow Y/Y Growth Statistics
High Average Low
129.23 % -34.39 % -169.29 %
(March 31, 2016)   (Dec 31 2023)
Net Cash Flow fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #2
Healthcare Sector #8
Overall #119
Net Cash Flow Y/Y Growth Statistics
High Average Low
129.23 % -34.39 % -169.29 %
(March 31, 2016)   (Dec 31 2023)

Net Cash Flow by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Prothena Public Limited's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PRTA's IV. Quarter Q/Q Net Cash Flow Comment
IV. Quarter 2023 accomplishment of -52.07 millions by Prothena Corporation Public Limited Company come out even worse compare to the net cash outflow -39.51 millions in the previous quarter.

Within Major Pharmaceutical Preparations industry Prothena Corporation Public Limited Company achieved highest sequential Net Cash Flow growth. While Prothena Public Limited's Net Cash Flow growth quarter on quarter, overall rank is .


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PRTA's IV. Quarter Q/Q Net Cash Flow Comment
IV. Quarter 2023 results of -52.07 millions by Prothena Corporation Public Limited Company look even less good compare to the net cash outflow -39.51 millions in the third quarter.

Within Major Pharmaceutical Preparations industry Prothena Corporation Public Limited Company achieved highest sequential Net Cash Flow growth. While Prothena Public Limited's Net Cash Flow growth quarter on quarter, overall rank is .


Prothena Public Limited's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Net Cash Flow 12 Months Ending $ -91.58 $ 92.66 $ 202.47 $ 144.05 $ 132.17
Y / Y Net Cash Flow Growth (TTM) - - 88.15 % -27.49 % -53.19 %
Year on Year Net Cash Flow Growth Overall Ranking # 157 # 469 # 323 # 430 # 421
Seqeuential Net Cash Flow Change (TTM) - -54.23 % 40.56 % 8.99 % -
Seq. Net Cash Flow Growth (TTM) Overall Ranking # 119 # 345 # 307 # 371 # 169




Cumulative Net Cash Flow growth Comment
Prothena Corporation Public Limited Company realized trailing twelve months net cash outflow of $ -92 millions, in the Dec 31 2023, compare to Net Cash Flow of $ 132 millions a year ago.

Among companies within the Healthcare sector 10 other companies have achieved higher trailing twelve month Net Cash Flow growth. While Total ranking has impoved so far to 157, from total ranking in previous quarter at 469.

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
129.23 %
-34.39 %
-169.29 %
 

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 2
Healthcare Sector # 11
Overall # 157

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
129.23 %
-34.39 %
-169.29 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 8
S&P 500 # 119
Cumulative Net Cash Flow growth Comment
Prothena Corporation Public Limited Company realized trailing twelve months net cash outflow of $ -92 millions, in the Dec 31 2023, compare to Net Cash Flow of $ 132 millions a year ago.

Among companies within the Healthcare sector 10 other companies have achieved higher trailing twelve month Net Cash Flow growth. While Total ranking has impoved so far to 157, from total ranking in previous quarter at 469.

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
129.23 %
-34.39 %
-169.29 %
 


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 2
Healthcare Sector # 11
Overall # 157

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
129.23 %
-34.39 %
-169.29 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 8
S&P 500 # 119




Other Net Cash Flow Growth
Major Pharmaceutical Preparations Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
PRTA's Net Cash Flow Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth
Net Cash Flow Growth for PRTA's Competitors
Net Cash Flow Growth for Prothena Public Limited's Suppliers
Net Cash Flow Growth for PRTA's Customers

You may also want to know
PRTA's Annual Growth Rates PRTA's Profitability Ratios PRTA's Asset Turnover Ratio PRTA's Dividend Growth
PRTA's Roe PRTA's Valuation Ratios PRTA's Financial Strength Ratios PRTA's Dividend Payout Ratio
PRTA's Roa PRTA's Inventory Turnover Ratio PRTA's Growth Rates PRTA's Dividend Comparisons



Companies with similar Net Cash Flow no change for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Dec 31 2023
Astrazeneca Plc-5.29%$ -5.287 millions
Lipocine Inc -6.98%$ -6.984 millions
Caredx Inc -14.62%$ -14.617 millions
Sophia Genetics Sa-16.41%$ -16.406 millions
Xencor Inc-17.78%$ -17.780 millions
Kronos Bio Inc -20.78%$ -20.784 millions
Earth Science Tech Inc -21.38%$ -21.381 millions
Hookipa Pharma inc -22.19%$ -22.193 millions
Anaptysbio Inc -24.22%$ -24.222 millions
Koru Medical Systems Inc-26.57%$ -26.570 millions
Abbott Laboratories-35.07%$ -35.069 millions
Lantheus Holdings Inc -37.16%$ -37.161 millions
Alcon inc -37.78%$ -37.778 millions
Inflarx N v -38.04%$ -38.037 millions
Novartis Ag-39.41%$ -39.413 millions
Argenx se-40.00%$ -40.005 millions
Gh Research Plc-40.04%$ -40.040 millions
Bright Minds Biosciences Inc -41.15%$ -41.154 millions
Enzon Pharmaceuticals inc -42.33%$ -42.332 millions
Myriad Genetics Inc -44.65%$ -44.653 millions
Elutia inc -46.46%$ -46.456 millions
Gilead Sciences Inc -46.70%$ -46.704 millions
Koninklijke Philips Nv-49.11%$ -49.110 millions
Avidity Biosciences Inc -49.45%$ -49.449 millions
Proqr Therapeutics N v -49.46%$ -49.460 millions
Protalix Biotherapeutics inc -49.52%$ -49.523 millions
Xeris Biopharma Holdings Inc -49.99%$ -49.994 millions
Altair International Corp -52.34%$ -52.344 millions
Macrogenics Inc -55.57%$ -55.574 millions
Atricure Inc -59.98%$ -59.983 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com